NasaClip Company Profile

Background

Overview

NasaClip is a Baltimore-based medical device company specializing in innovative solutions for nosebleed management. Founded in 2015 by Dr. Elizabeth Clayborne, an emergency physician and entrepreneur, the company has developed the first adjustable, hands-free nosebleed rescue device. This device provides constant, comfortable compression combined with intranasal sponges that can be medicated, offering a non-invasive and effective treatment for nosebleeds in various settings.

Mission and Vision

NasaClip's mission is to empower individuals and healthcare providers with a simple, effective solution for managing nosebleeds, thereby reducing unnecessary emergency room visits and associated healthcare costs. The company's vision is to become a leading provider of non-invasive medical devices that enhance patient care and streamline healthcare processes.

Industry Significance

Nosebleeds are a common medical issue, with over 500,000 emergency room visits annually in the U.S. Traditional treatments can be invasive and costly. NasaClip's innovative approach addresses this gap by providing a portable, user-friendly device that offers immediate relief, thereby improving patient outcomes and reducing the burden on healthcare facilities.

Key Strategic Focus

Core Objectives

Product Development: Enhance and expand the NasaClip device line to cater to a broader range of patients and healthcare settings.

Market Expansion: Increase product availability through partnerships with healthcare providers, retailers, and direct-to-consumer channels.

Innovation: Develop additional features, such as medicated sponges, to improve treatment efficacy and patient comfort.

Areas of Specialization

Medical Devices: Design and manufacture devices focused on non-invasive treatments for common medical conditions.

Nosebleed Management: Specialize in providing effective solutions for nosebleed control in various environments.

Key Technologies Utilized

Adjustable Compression Mechanism: Allows for personalized pressure application to effectively control bleeding.

Intranasal Sponges: Facilitate medication delivery and enhance clot formation within the nasal passages.

Primary Markets Targeted

Healthcare Facilities: Hospitals, clinics, and urgent care centers.

Retailers: Pharmacies and general retailers for over-the-counter sales.

Direct-to-Consumer: Online platforms and home healthcare markets.

Financials and Funding

Funding History

Total Funds Raised: Approximately $3.5 million from venture capital and angel investors, along with $256,000 in non-dilutive grants from the National Science Foundation's SBIR Phase I program.

Recent Funding Rounds

Crowdfunding Campaign: In 2024, NasaClip raised $2.6 million through a crowdfunding campaign on Wefunder, surpassing its initial target of $500,000.

TEDCO Investment: In 2023, the Maryland Technology Development Corporation (TEDCO) invested $500,000 from its Social Impact Funds to support NasaClip's growth.

Notable Investors

TEDCO: Provided multiple investments totaling $1 million, including a $500,000 investment in 2023.

National Science Foundation (NSF): Awarded a $256,000 SBIR Phase I grant to assist with the development of a medicated version of the device.

Utilization of Capital

Product Development: Enhancing device features and expanding the product line.

Marketing and Sales: Increasing brand awareness and expanding market reach.

Operational Expansion: Scaling manufacturing capabilities and improving distribution channels.

Pipeline Development

Key Pipeline Candidates

Medicated NasaClip: Development of intranasal sponges that can deliver medications, such as vasoconstrictors and opioid reversal agents like Naloxone, to enhance treatment efficacy.

Stages of Development

Product Development: Ongoing research and development to integrate medicated sponges into the NasaClip device.

Clinical Trials: Planned studies to evaluate the safety and efficacy of the medicated version.

Target Conditions

Nosebleeds: Primary focus on anterior nosebleeds.

Opioid Overdoses: Potential application of Naloxone delivery for emergency situations.

Anticipated Milestones

Product Launch: Introduction of the medicated NasaClip device in the next 12-18 months.

Regulatory Approval: Securing FDA clearance for the medicated version.

Technological Platform and Innovation

Proprietary Technologies

Adjustable Compression Mechanism: Enables personalized pressure application to effectively control bleeding.

Intranasal Sponges: Facilitate medication delivery and enhance clot formation within the nasal passages.

Significant Scientific Methods

Clinical Research: Ongoing studies to assess the safety and efficacy of the NasaClip device and its medicated versions.

Product Testing: Rigorous testing protocols to ensure device reliability and patient safety.

Leadership Team

Key Executives

Dr. Elizabeth Clayborne: Founder and CEO. An emergency physician and entrepreneur, Dr. Clayborne developed the NasaClip device to address the common issue of nosebleeds in emergency settings.

Romil Patel: Co-founder and CFO. Brings financial expertise to the company, overseeing financial operations and strategic planning.

Dr. Neal Sikka: Co-founder. An emergency physician who contributed to the development and clinical validation of the NasaClip device.

Social Media

Instagram

Facebook

Twitter

Competitor Profile

Market Insights and Dynamics

The global market for nosebleed treatment devices is expanding, driven by technological advancements and the increasing demand for non-invasive treatment options. NasaClip's innovative approach positions it favorably within this growing market.

Competitor Analysis

Traditional Treatments: Methods such as nasal packing and cauterization are commonly used but can be invasive and uncomfortable.

Emerging Solutions: Other companies are developing devices for nosebleed management, but NasaClip's unique combination of adjustable compression and medicated sponges offers a distinct advantage.

Strategic Collaborations and Partnerships

SourceMark Medical Partnership

In October 2023, NasaClip partnered with SourceMark Medical to expand access to its nosebleed treatment device, aiming to streamline the treatment process and improve patient outcomes.

Operational Insights

Strategic Considerations

Market Penetration: Focus on increasing brand awareness and adoption among healthcare providers and consumers.

Competitive Advantage: Leverage the unique features of the NasaClip device, such as its hands-free design and potential for medicated applications, to differentiate from competitors.